评论文章:预防炎症性肠病--前进之路

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Alimentary Pharmacology & Therapeutics Pub Date : 2024-10-15 DOI:10.1111/apt.18263
Sérgio Bronze, Manasi Agrawal, Jean-Frédéric Colombel, Joana Torres, Ryan C. Ungaro
{"title":"评论文章:预防炎症性肠病--前进之路","authors":"Sérgio Bronze,&nbsp;Manasi Agrawal,&nbsp;Jean-Frédéric Colombel,&nbsp;Joana Torres,&nbsp;Ryan C. Ungaro","doi":"10.1111/apt.18263","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The possibility of preventing inflammatory bowel disease (IBD) is becoming more plausible due to advances in understanding preclinical disease and successful prevention trials in other immune-mediated diseases, such as type 1 diabetes and rheumatoid arthritis. However, before that possibility becomes reality, several efforts need to occur in parallel and in a coordinated way.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>To propose some critical steps necessary for advancing the field of IBD prediction and prevention.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We reviewed the current literature to identify the necessary steps toward a preventive strategy for IBD.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The first step should determine the most robust predictive biomarkers and validate them across independent cohorts, creating a multidimensional predictive tool. The second step is to gain a better understanding of the preferences of first-degree relatives and people at risk for IBD, informing the implementation of screening and preventive strategies. Third, these efforts should contribute to the development of high-risk clinics and establish the necessary networks for disease prevention trials.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Advancing the field of IBD prediction and prevention will require a multifaceted approach, integrating biomarker discovery, understanding patient preferences, and establishing infrastructure for a collaborative network to support the practical implementation of IBD prevention strategies.</p>\n </section>\n </div>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"60 9","pages":"1166-1175"},"PeriodicalIF":6.6000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18263","citationCount":"0","resultStr":"{\"title\":\"Review article: Prevention of inflammatory bowel disease—The path forward\",\"authors\":\"Sérgio Bronze,&nbsp;Manasi Agrawal,&nbsp;Jean-Frédéric Colombel,&nbsp;Joana Torres,&nbsp;Ryan C. Ungaro\",\"doi\":\"10.1111/apt.18263\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>The possibility of preventing inflammatory bowel disease (IBD) is becoming more plausible due to advances in understanding preclinical disease and successful prevention trials in other immune-mediated diseases, such as type 1 diabetes and rheumatoid arthritis. However, before that possibility becomes reality, several efforts need to occur in parallel and in a coordinated way.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>To propose some critical steps necessary for advancing the field of IBD prediction and prevention.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We reviewed the current literature to identify the necessary steps toward a preventive strategy for IBD.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The first step should determine the most robust predictive biomarkers and validate them across independent cohorts, creating a multidimensional predictive tool. The second step is to gain a better understanding of the preferences of first-degree relatives and people at risk for IBD, informing the implementation of screening and preventive strategies. Third, these efforts should contribute to the development of high-risk clinics and establish the necessary networks for disease prevention trials.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Advancing the field of IBD prediction and prevention will require a multifaceted approach, integrating biomarker discovery, understanding patient preferences, and establishing infrastructure for a collaborative network to support the practical implementation of IBD prevention strategies.</p>\\n </section>\\n </div>\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\"60 9\",\"pages\":\"1166-1175\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18263\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/apt.18263\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.18263","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景 由于对炎症性肠病 (IBD) 临床前研究的进展,以及对其他免疫介导疾病(如 1 型糖尿病和类风湿性关节炎)预防试验的成功,预防炎症性肠病 (IBD) 的可能性正变得越来越大。然而,在这种可能性变为现实之前,需要同时协调开展多项工作。 目的 提出推进 IBD 预测和预防领域所需的一些关键步骤。 方法 我们回顾了现有文献,以确定 IBD 预防策略的必要步骤。 结果 第一步应确定最可靠的预测生物标志物,并在独立队列中对其进行验证,从而创建一个多维预测工具。第二步是更好地了解一级亲属和 IBD 高危人群的偏好,为筛查和预防策略的实施提供信息。第三,这些工作应有助于高风险诊所的发展,并为疾病预防试验建立必要的网络。 结论 推进 IBD 预测和预防领域的发展需要采取多方面的方法,将生物标记物的发现、了解患者的偏好和建立合作网络的基础设施结合起来,以支持 IBD 预防策略的实际实施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Review article: Prevention of inflammatory bowel disease—The path forward

Background

The possibility of preventing inflammatory bowel disease (IBD) is becoming more plausible due to advances in understanding preclinical disease and successful prevention trials in other immune-mediated diseases, such as type 1 diabetes and rheumatoid arthritis. However, before that possibility becomes reality, several efforts need to occur in parallel and in a coordinated way.

Aim

To propose some critical steps necessary for advancing the field of IBD prediction and prevention.

Methods

We reviewed the current literature to identify the necessary steps toward a preventive strategy for IBD.

Results

The first step should determine the most robust predictive biomarkers and validate them across independent cohorts, creating a multidimensional predictive tool. The second step is to gain a better understanding of the preferences of first-degree relatives and people at risk for IBD, informing the implementation of screening and preventive strategies. Third, these efforts should contribute to the development of high-risk clinics and establish the necessary networks for disease prevention trials.

Conclusions

Advancing the field of IBD prediction and prevention will require a multifaceted approach, integrating biomarker discovery, understanding patient preferences, and establishing infrastructure for a collaborative network to support the practical implementation of IBD prevention strategies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
期刊最新文献
Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease? Editorial: Updated COVID-19 Boosters-Tailoring Protection for Patients With IBD. Authors' Reply. Review Article: Green Management of IBD-New Paradigms for an Eco-Friendly Approach. Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1